Increase in Patients with Heart Disease Fuels the Biomarker R&D Segment

Growing Concerns Over Heart Diseases 

When it comes to discussing heart related matters the news is not good as the number of patients with heart diseases is increasing rapidly. According to a journal named “The Lancet “the number of patients with peripheral arterial disease has increased by almost 24% in just a decade, between 2000 to 2010. These patients suffer plaque accumulation in their arteries and are at greater risk of stroke or heart attack, says research analysts at the Allied Market Research. Industry experts eyeing the size and share, growth and technology advancements in cardiac biomarkers segment further explain that there has been a significant rise in patients with heart rhythm disorder afib. Lancet’s study outlines that about 2.7 million public in America have afib. These factors will drive the sales of the cardiac biomarkers market worldwide. 

Watch Some Clinical Benefits of Critical Diagnostics by Cardiac Biomarker ST2
https://www.youtube.com/watch?v=VySAOdOQyxk

Region-wise Growth of the Cardiac Biomarkers Market

Earlier most of the research as well as the commercials focus of pharma and diagnostics companies was on Western regions including the United States and Europe. But the focus has finally shifted to some of the emerging markets such as China, Brazil, India, and Russia. A distinct difference has been spotted when it comes to biomarkers response to the drugs developed in countries located in the West and even in the clinical features and pathophysiology of diseases. Undoubtedly, changes in lifestyle and different dietary preference as well as genetic backgrounds across different nations have contributed to this. Thus, more research is required to curb major challenges. Backed by a growing economic power, the fast emerging markets such as China and India are planning on investing generously in biomarker research and developments to enhance the current therapeutic treatments and create more opportunities for personalized drugs in the cardiac biomarkers market.

In the United States alone, there are over 49 million BNP, Myocardial muscle Creatine Kinase, Troponins (T and I) and other assays performed every year. At a price of over $5 to 24 per test, the current market is estimated between $298 million to $1.24 billion. Moreover, if advanced cardiac biomarkers were made accessible, recent study outlines that an additional $ 5.5 million of the acute and over $ 40 million of the chronic test can be carried out for heart failure monitoring and discharge alone. This can result in the cardiac biomarkers market potential between $38 million to more than $1billion.  

Flip Through a Presentation by Dr. Anurag Yadav On “ Cardiac biomarker past, today and future 
http://www.slideshare.net/anurag_yadav/cardiac-biomarker-past-today-and-future

Adopting Optimistic Approach Creates Greater Opportunities in Cardiac Biomarkers Market

Adopting an optimistic approach is what many biomarker researchers believe can put several challenges to rest. In the biomarker industry the key to discovery is definitely funding, which has increased the opportunities for translational medicine worldwide. This, coupled with the recent downsizing of the activities especially in internal biomarker in prominent brands, is a significant stimulation for new business opportunities. Several spin-off manufacturers have been established this year and many of them have even entered into a contract with different research institutions, laboratories as well as reputed vendors. Such collaborative efforts with prominent brands, enterprises, and universities is expected to drive both pharmaceutical as well as diagnostics biomarker development.  Most importantly, this type of functional network now includes many emerging markets and their aging population, keeping the biomarker research and development across the globe robust.  

Nature of Funding Offers Greater Opportunity in Cardiac Biomarkers Market
Nature of funding, especially in the translational medicine, will open new avenues for the biomarker market. Today funding agencies are backing multicenter consortia generally in the public – private partnership over single laboratories. This is finally bringing together researchers specializing in basic as well as applied biomarker and ensuring a result -oriented knowledge transfer and concentrate more on applied biomarker research. 

Major Announcements in 2016 

Researchers at the famous Mayo Clinic made news after introducing to the world an accurate method that helps in measuring the circulatory factor known as GDF11. Scientists at the clinic outline that the method can offer a better understanding about its potential influence on aging. These scientists discovered that GDF11 does not decline with man’s chronological age, but can be linked with different signs of biological ages such as fragility, certain chronic ailments, and higher risk in elders with cardiovascular problems. Commenting on this Nathan LeBrasseur, Ph.D., the director at the famous Mayo Clinic said "Aging is the primary risk factor for the majority of chronic diseases, so it is critical to identify and understand the biomarkers, or indicators, in the body that are linked to this process." LeBrasseur explained "The role of GDF11 as a biomarker of aging and its association with age-related conditions has been largely contradictory, in part, because of how difficult it has been to measure. We have developed a new way to measure GDF11 that is accurate and effective."

EU-funded EU-MASCARA project has been focusing on applying advanced biomarkers in the way that they help medical practitioners operating in the risk prediction as well as early intervention. The project has been backed by contribution from some of the small and medium enterprises in areas of technology research including biomarker testing, data management and assessment as well as assay development. While the research and developments is often expensive and time consuming process, opportunities for advanced analytical tools that can provide accuracy and cost less is significant. The team working on the project is now determined to combine the advanced biomarkers with the existing ones to design a highly cohesive risk predictive model. 

 

Related Post